BILLERICA, Massachusetts – March 1st, 2018 – Bruker today announced the appointment of Dr. Burkhard Prause, the President of the Bruker Energy & Supercon Technologies (BEST) segment, as an executive officer of Bruker Corporation. Dr. Prause has a successful track record of leading BEST through a significant expansion of its business in the last decade, with a focus on customer needs, productivity, quality and innovation.
Dr. Prause has been with Bruker for over 15 years, most recently as President of BEST since April 2008. He was a director of BEST from April 2012 to February 2013. He has also served in leadership roles at various BEST subsidiaries, including as a director of Hydrostatic Extrusions Ltd. since April 2013, and as a Managing Director of Bruker EAS GmbH and Bruker HTS GmbH since January 2005, RI Research Instruments GmbH since December 2008, and Bruker ASC GmbH since March 2009. Dr. Prause began his career at Bruker with the company’s BioSpin preclinical MRI business in 2002. Prior to joining Bruker, Dr. Prause was a senior staff scientist at the Max-Planck Institute in Tuebingen, Germany. Dr. Prause holds a Ph.D. in physics from the University of Notre Dame in Indiana.
Frank Laukien, President and CEO of Bruker Corporation, stated: “I am pleased to welcome Burkhard to Bruker’s executive leadership team. His outstanding contributions to the reshaping and profitable growth of our BEST segment over the past decade make him an excellent addition to Bruker’s senior management and leadership team.”
Dr. Prause commented: “The BEST business has seen extraordinary growth in serving our MRI and ‘Big Science’ markets in recent years, both organically and through the successful acquisition of Bruker OST. Our development of high-performance superconducting technologies is a major innovation force within Bruker, and a strategic requirement for NMR. This appointment as executive officer, and the strong integration in Bruker, gives BEST additional momentum to drive profitable growth and to advance key enabling technologies for Bruker, for the major MRI companies as well as for the high-energy physics community.”
About Bruker Corporation (NASDAQ: BRKR)
For more than 55 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, phenomics and proteomics research, microbiology and molecular pathology research.
Head of Investor Relations
T: +1 (978) 663-3660, ext. 1479